ArticlemedRxiv : the preprint server for health sciences2026

Combining VEGFR tyrosine kinase inhibitors and PD-1/PD-L1 inhibitors versus VEGFR tyrosine kinase inhibitors monotherapy in renal cell carcinoma: a target trial emulation.

Daling Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.